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1. ABSTRACT 
Ketoprofen is a non-steroidal anti-inflammatory drug belonging to the 2-arylpropionic acid 
group. It has been widely used in domestic animals because of its anti-inflammatory, antipyretic and 
analgesic actions. Ketoprofen is a chiral compound existing in two enantiomeric forms, S (+) and R 
(-) ketoprofen. Each enantiomer has different pharmacodynamic and pharmacokinetic properties. 
The commercial products in veterinary medicine are 50:50 racemic mixtures of both enantiomers. 
Ketoprofen undergoes unidirectional chiral inversion from the R- to the S-enantiomer, the extent of 
inversion being about 70% in pigs. The aims of this thesis research were to investigate the oral 
bioavailability, enantiospecific plasma concentrations and efficacy of racemic ketoprofen after oral 
administration in pigs.  
 
Total plasma concentrations of ketoprofen were investigated in a randomized crossover design. 
Racemic ketoprofen was administered at 3 mg/kg and 6 mg/kg po, and 3 mg/kg im and iv. The 
bioavailability of oral ketoprofen was almost complete. Bioequivalence could not be detected 
between oral and intramuscular administration routes.  
 
Plasma concentrations of S- and R-ketoprofen after oral (4 mg/kg) and intramuscular (3 mg/kg) 
routes of administration of racemic ketoprofen in pigs were determined in crossover design. S-
ketoprofen was the predominant enantiomer in pig plasma after administration of the racemic 
mixture via both routes. The maximum plasma concentration of S-ketoprofen was more than twice 
as high as that of R-ketoprofen, and the terminal half-life was approximately three times greater for 
S-ketoprofen than R-ketoprofen with both administration routes. The mean (± SD) relative 
bioavailability (po compared to im) was 83 ± 20% and 63 ± 23% for S-ketoprofen and R-
ketoprofen, respectively. Although some differences were detected in the plasma concentrations of 
ketoprofen enantiomers after different routes of administration, they are probably not relevant in 
clinical use. Thus, the pharmacological effects of racemic ketoprofen are considered to be 
comparable after intramuscular and oral routes of administration in growing pigs. 
 
The efficacy of orally administered racemic ketoprofen in endotoxemia in pigs was assessed in 
an E. coli endotoxin challenge trial. The growing pigs were challenged intravenously with E. coli 
endotoxin and one hour after the challenge were treated with ketoprofen at dose rates of 0.5 mg/kg, 
1 mg/kg, 2 mg/kg and 4 mg/kg or with tap water. The body temperature was measured and a total 
clinical score was calculated after assessing the general behaviour, respiratory rate and locomotion 
of the pigs. Thromboxane B2 and ketoprofen concentrations were analysed from blood samples. 
Ketoprofen treatment significantly reduced the rectal temperature and total clinical scores, and 
lowered the blood thromboxane B2 concentrations when compared to the control group. Ketoprofen 
plasma concentrations were lower than previously reported in healthy pigs after similar doses. Two 
mg/kg can be considered a sufficient oral dose of ketoprofen for treating endotoxemia in pigs, as 
increasing the dose above this did not further increase the effect. 
 
 
 
 
 
Lameness is a common problem among sows and gilts. It often leads to poor animal 
welfare and economic losses because of unplanned culling. Locomotor disorders cause severe pain, 
and lame animals need to be treated accordingly. A field trial was conducted to examine the 
efficacy and compare two doses of oral administration of racemic ketoprofen in the treatment of 
clinical lameness caused by non-infectious musculoskeletal disorders in sows and gilts. Dose rates 
of 2 mg/kg and 4 mg/kg of oral ketoprofen were compared to placebo treatment over five 
consecutive days in a double-blinded study. Lameness was assessed with a five-grade scoring 
system prior to and on the last day of the treatment. This study demonstrated that oral ketoprofen 
was efficient in alleviating the signs of non-infectious lameness in sows and gilts. The rate of 
treatment success was 54.3% for the ketoprofen 4 mg/kg group, 53.2% for the ketoprofen 2 mg/kg 
group and 20.8% for the pigs in the placebo group. There was no difference in efficacy between the 
two ketoprofen doses. Oral ketoprofen appeared to be a practical way to alleviate pain and improve 
the welfare of lame sows. The findings support the use of ketoprofen at a dose rate of 2 mg/kg in 
treating locomotor disorders in pigs. 
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3. ABBREVIATIONS 
AUC  area under the time-concentration curve 
AUC0-∞  area under the time-concentration curve from time 0 to infinity 
β  rate constant of the elimination phase 
Cmax  maximum plasma concentration 
CI  confidence interval 
CL  total clearance 
CMH  Cochran-Mantel-Haenszel 
COX  cyclooxygenase 
F  bioavailability 
Frel  relative bioavailability 
HPLC  high-performance liquid chromatography 
IC50  the half maximal inhibitory concentration 
im  intramuscular 
ip  intraperitoneal 
iv  intravenous 
KTP  ketoprofen 
LC-MS/MS liquid chromatography-mass spectrometry 
LOQ  limit of quantification 
MAT  mean absorption time 
MRT  mean residence time 
NSAID  non-steroidal anti-inflammatory drug 
PCV  packed cell volume 
PDS  postpartum dysgalactia syndrome 
PK/PD  pharmacokinetics/pharmacodynamics 
po  per os 
SD  standard deviation 
SEM  standard error of the mean 
Tmax  time to maximum plasma concentration 
t1/2  elimination half-life 
TXB2  thromboxane B2 
Vd  volume of distribution 
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4. INTRODUCTION 
Animal welfare, legislation, environmental aspects, public health and food safety, as well as 
economics are among the issues to be considered when production animals are treated. Medication 
in veterinary medicine is strongly controlled by EU and national legislation. Veterinary medicinal 
products may only be administered to food producing animals if marketing authorization has been 
issued. In cases where there is no authorized medicinal product for a condition, a veterinary 
medicinal product authorized for use in another production animal species or for another condition 
in the same species may be used (2001/82/EEC). The use of some active substances is prohibited in 
animals because of their potential risk for public health (some antibiotics and substances for which 
safe minimal residue limits cannot be established) or animal welfare reasons (growth promoters) 
(96/22/EC).  The use of medicinal products must not cause harm to the environment, either.  
 
The treatment of production animals should be economically feasible. The withdrawal periods, 
the length of treatment and the cost of medication must be taken into consideration when animals 
are medicated. In some cases, euthanasia may be the preferred choice because of animal welfare or 
economics.  
 
Pain and painful procedures performed in animals are the most common and emotive concerns 
among the public (Weary et al., 2006). Recognizing pain in animals is sometimes difficult and they 
might therefore be left untreated (Raekallio et al., 2003; Weary et al., 2006). Treatment may also 
cause pain, tissue irritation and side effects, which must be considered particularly when the 
duration of medication is prolonged (Bath, 1998; Pyörälä et al., 1999). Many infectious diseases 
cause a fever, which often leads to impaired appetite. In young animals, a reduced food intake or 
anorexia decreases growth rates, and in neonatal animals may lead to death. Antipyretic medication 
is therefore important as a supportive treatment.  
 
Mastitis caused by Gram-negative bacteria, particularly Eschericia coli, is the most common 
cause of post-partum dysgalactia in sows (Wagner, 1982; Martineau et al., 1992; Reiner et al., 2009; 
Papadopoulos et al., 2010). The infection often induces a serious endotoxemic condition that leads 
to decreased milk production by the sow. Hypogalactia has the most important impact on 
production, as it will eventually lead to increased mortality among the piglets (Reiner et al., 2009). 
The treatment recommendation includes the use of NSAIDs with antimicrobials to inhibit bacterial 
growth and endotoxin production (Hirsch et al., 2003). 
 
Lameness is a common problem among sows, and will often lead to premature culling or 
euthanasia of the lame animal (Kirk et al., 2005; Anil et al., 2009). It causes economic losses and 
ethical concerns in relation to animal welfare (Chagnon et al., 1991). In Finland, 9% of loose-
housed sows have been found to be lame (Heinonen et al., 2006). The most common reasons for 
lameness are arthrosis or arthritis (Dewey et al., 1993; Kirk et al., 2005, Heinonen et al., 2006).  
Environmental aspects have a notable effect on the incidence of lameness at the farm level 
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(Kroneman et al., 1993; Heinonen et al., 2006). The improvement of environmental conditions does 
not eliminate the whole problem, and lame animals have to be treated properly. Musculoskeletal 
disorders may cause severe pain, and the relief of pain therefore has to be considered. The treatment 
of production animals has to be ethically acceptable and the need for pain relief should not be 
underestimated. 
 
Ketoprofen is an NSAID belonging to the 2-arylpropionic acid group. It has been widely used in 
domestic animals because of its anti-inflammatory, antipyretic and analgesic actions. Ketoprofen is 
a chiral compound existing in two enantiomeric forms S (+) and R (-) ketoprofen. Each enantiomer 
has different pharmacodynamic and pharmacokinetic properties (Tucker and Lennard, 1990; 
Landoni et al., 1997). The commercial products in veterinary medicine are 50:50 racemic mixtures 
of both enantiomers. In the European Union, the need to set a maximum residue limit (MRL) for 
ketoprofen for bovine, porcine and equine animals has been assessed to protect public health, and it 
has been concluded that ketoprofen can be included in Annex II of the MRL regulation, i.e. 
ketoprofen is not subject to maximum residue limits (EC, 37/2010). The withdrawal time for meat 
is 2 to 4 days after intramuscular use, depending on the product, and 1 day after per oral use.  
 
This dissertation concerns the pharmacokinetics of orally administered racemic ketoprofen in 
pigs and the efficacy of ketoprofen treatment in two common conditions for which the use of 
NSAIDs is indicated.  
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5. REVIEW OF THE LITERATURE 
5.1 Ketoprofen  
 
Ketoprofen, 2-(phenyl 3-benzoyl) propionic acid, is an NSAID belonging to the 2-arylpropionic 
acid group. It is a chiral compound existing in two enantiomeric forms, S (+) and R (-) ketoprofen. 
Ketoprofen undergoes unidirectional chiral inversion from the R- to the S-enantiomer in many 
animal species (Menzel et al., 1994; Aberg et al., 1995; Landoni and Lees, 1995b; Castro et al., 
2000; Verde et al., 2001; Igarza et al., 2002; Arifah et al., 2003; Neirinckx et al., 2011). The 
mechanism involves stereoselective activation of R-ketoprofen by the formation of coenzyme A 
thioester, enzymatic epimerization of R-thioester to S-thioester and hydrolysis of S-thioester 
(Wechter et al., 1974; Hutt and Caldwell, 1983). The liver seems to have predominant role in the 
inversion process, although it takes place in various other organs as well, such as the intestine, lungs 
and kidneys (Cox et al., 1985; Mehvar and Jamali, 1988; Hall et al., 1992). The extent of inversion 
varies between species. Thioesterification, which is considered to be the limiting step of the chiral 
inversion process, is selective for the same aryl-2-propionic acid in various species (Soraci and 
Benoit, 1995).  
 
 
5.1.1 Ketoprofen in pigs 
 
Intramuscular use of racemic ketoprofen is currently licensed for pigs in the European Union at 
a dose rate of 3 mg/kg for the treatment of porcine agalactia syndrome and respiratory tract 
infections (EMEA, 1996). In 2009, an oral solution (Dinalgen 300 mg/ml, Laboratios Dr Esteva 
S.A., Barcelona, Spain) was granted marketing authorization in several EU countries for the 
treatment of fever and dyspnea associated with respiratory disease in fattening pigs at a dose rate of 
1.5–3 mg/kg administered in drinking water (Irish Medicines Board, 2010). The maximum length 
of medication is three days for both administration routes. The withdrawal time for meat is 2 to 4 
days after intramuscular use, mainly because of trace levels of residues at the injection site and 
depending on the product, and 1 day after per oral use.  
 
Although ketoprofen has been indicated in pigs for its anti-inflammatory, analgesic and 
antipyretic activities for almost 20 years, there have been few reports on its clinical efficacy in pigs. 
Its potent antipyretic activity has been shown in pigs challenged with Actinobacillus 
pleuropneumoniae and E. coli endotoxin, and in field conditions in fattening pigs with respiratory 
diseases and sows with PDS (Arnaud and Consalvi, 1994; Swinkels et al., 1994; Salichs et al., 
2012). In pigs challenged with Actinobacillus pleuropneumoniae, food consumption was also 
improved (Swinkels et al., 1994). Ketoprofen was administered orally at dose of 1.5 mg/kg in the E. 
coli endotoxin challenge study (Salichs et al., 2012) and intramuscularly at dose of 3 mg/kg in the 
other studies (Arnaud and Consalvi, 1994; Swinkels et al., 1994).   
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5.1.2 Pharmacokinetics of ketoprofen in pigs 
 
Orally-administered racemic ketoprofen is absorbed well in pigs, and bioavailability is almost 
complete (Larsen et al., 1991; Neirinckx et al., 2011a). Bioavailability is also high after oral 
administration of R-ketoprofen alone (Neirinckx et al., 2011b). The absorption was reported to be 
nonstereoselective, as no presystemic inversion was present (Neirinckx et al., 2011b). 
Transcutaneous permetration of racemic ketoprofen is also reported to be nonstereoselective (Panus 
et al., 1999). 
 
The predominant enantiomer in pig plasma is S-ketoprofen (Table 1) (Fosse et al., 2011a; Fosse 
et al., 2011b; Neirinckx et al., 2011a). The data of Fosse et al. (2011a) were obtained in neonatal 
animals (less than three weeks of age) and the data of Neirinckx et al. (2011a) in weaners 
(approximately 3 months of age). The pharmacokinetics of neonatal animals has some characteristic 
features. In general, the clearance is lower, the elimination half-life is longer and the volume of 
distribution larger in neonates compared to adults (Lees et al., 2004). The kinetics of ketoprofen is 
linear and the elimination half-life relatively short; approximately 0.5 h and 3.5 h for R-ketoprofen 
and S-ketoprofen, respectively (Fosse et al., 2011a; Fosse et al., 2011b; Neirinckx et al., 2011a). 
The maximum plasma concentration of R-ketoprofen is about the half of maximum plasma 
concentration of S-ketoprofen after oral and intramuscular administration of racemic ketoprofen 
(Fosse et al., 2011b; Neirinckx et al., 2011a). The inversion rate of R-ketoprofen to S-ketoprofen is 
rapid and high, approximately 70%, in pigs after po administration of R-ketoprofen (Neirinckx et 
al., 2011b). The inversion is mainly responsible for the faster clearance of R-ketoprofen after the 
administration of racemic ketoprofen. Stereoselectivity in protein or tissue binding, hepatic 
metabolism and renal excretion have not been studied in pigs and their influence cannot be 
completely excluded. The volume of distribution is low for both enantiomers with no differences 
between them (EMEA, 1996; Fosse et al., 2011a; Neirinckx et al., 2011a; Neirinckx et al., 2011b). 
Ketoprofen is highly bound to plasma protein and expected to distribute primarily to the 
extracellular fluids. Oral and intramuscular administration routes are likely to achieve smaller 
extravascular penetration than intravenous administration, which provides high initial plasma 
concentrations (Lees et al., 2004). Ketoprofen is converted into a carbonyl-reduced derivative, 2-
(phenyl 3-alphahydroxybenzoyl) propionic acid in pigs (EMEA, 1996). After a single intramuscular 
injection of 14C-ketoprofen (3 mg/kg), 70% of the total radioactivity was excreted via urine within 
96 hours, with most being excreted within 24 hours, and only 20% was recovered in faeces (EMEA, 
1996). In urine, about 30% of the radioactivity was due to 2-(phenyl 3-alphahydroxybenzoyl) 
propionic acid, 12% to the parental compound and 45% to polar components (EMEA, 1996).  
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Table 1. Mean (95% CI) / ± SD pharmacokinetic parameters after administration of racemic 
ketoprofen in pigs. 
    Dose   
  6 mg/kg iv1 6 mg/kg im2 3 mg/kg po3 
S-ketoprofen       
T½ (h) 3.3 (2.8–3.7) 3.5 (3.5–3.6) 2.2 ± 0.4 
MRT (h) 4.6 (3.9–5.5) 
 
3.9 ± 1.0 
AUC0-∞ (µgh/mL) 88.9 (71.1–111.1) 76.6 (63.2–92.9) 31.3 ±6.7 
Cmax (µg/mL) 19.1 (17.3–21.1) 13.1 (11.9–14.5) 7.3 ± 1.6 
Tmax (h) 
 
0.68 (0.51–0.84) 0.6 ± 0.3 
    R-ketoprofen       
T½ (h) 0.4 (0.3–0.5) 0.5 (0.5–0.6) 0.8 ± 0.2 
MRT (h) 0.5 (0.4–0.6) 
 
1.3 ± 0.3 
AUC0-∞ (µgh/mL) 7.1 (5.3–9.4) 7.5 (6.1–9.2) 4.3 ± 1.1 
Cmax (µg/mL) 10.1 (8.2–12.5) 7.0 (5.9–8.3) 3.9 ± 1.1 
Tmax (h)   0.3 (0.2–0.3) 0.3 ± 0.2 
1Fosse et al., 2011a; 2Fosse et al., 2011b; 3Neirinckx et al., 2011a.  
 
 
5.1.3. Enantiospecific pharmacokinetics of ketoprofen in other animal species 
 
The enantiospecific pharmacokinetics of ketoprofen have been studied in several production 
animal species other than pigs, including llamas (Navarre et al., 2001), calves ( Landoni et al., 
1995b; Landoni and Lees, 1995b), dairy cattle (Igarza et al., 2004), horses (Jaussaud et al., 1993; 
Landoni and Lees, 1996; Verde et al., 2001), sheep (Arifah et al., 2001; Landoni et al., 1999) and 
goats (Arifah et al., 2003). In most animal species, such as rats (Foster and Jamali, 1988), dogs 
(Montoya et al., 2004), cats (Lees et al., 2003) and horses (Verde et al., 2001), S-ketoprofen is the 
predominant enantiomer in the plasma after administration of the racemic drug, whilst R-ketoprofen 
is predominant in sheep (Arifah et al., 2001), camels (Al Katheeri et al., 2000) and elephants 
(Hunter et al., 2003). The plasma concentrations of both enantiomers are equal in goats (Arifah et 
al., 2003), calves (Landoni et al., 1995b; Landoni and Lees, 1995b), llamas (Navarre et al., 2001) 
and humans (Sallustio et al., 1988). Plasma concentrations of both enantiomers have been reported 
to be higher in female camels than males, and stereoselectivity in the pharmacokinetics of racemic 
ketoprofen was more evident in females than males (Al Katheeri et al., 2000). Gender dependence 
of urinary excretion of conjugated S-ketoprofen and a faster total clearance of S-ketoprofen in 
males than in females has been reported in rats (Palylyk and Jamali, 1992), whereas in a human 
study the elimination rate constant for R-ketoprofen was higher in males than females (Rudy et al., 
1998). The pharmacokinetic parameters of S- and R-ketoprofen in different large animal species 
after iv administration of racemic ketoprofen are presented in Table 2. The elimination half-life of 
ketoprofen enantiomers is relatively short in all animal species studied. Measurable concentrations 
are detected in exudate much longer than in plasma, which may be due to a high level of plasma 
protein binding and protein, with bound drug, leaking into exudate from plasma (Arifah et al., 2001; 
Arifah et al., 2003; Landoni et al., 1995b; Landoni et al., 1999). 
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Table 2. Mean ± SEM (goat, horse, calf, sheep)/ ±SD (llama)/ range (camel, elephant) 
pharmacokinetic parameters for S- and R-ketoprofen after iv administration of racemic 
ketoprofen to different large animal species. 
          
Parameter 
(unit)     
  
S-ketoprofen     R-ketoprofen     
 
Dose 
(mg/kg) T½ (h) MRT (h) 
AUC0-∞ 
(µgh/mL) T½ (h) MRT (h) 
AUC0-∞  
(µg /mL) 
Goat1 3 1.79± 0.24 1.28 ± 0.2  5.15 ± 0.46 1.87 ± 0.28 1.36 ± 0.29 6.81 ± 0.66 
Horse2 2.2 1.14 ± 0.18 0.93 ± 0.13  5.54 ± 0.98 1.87 ± 0.63 1.40 ± 0.51 3.13 ± 0.50 
Camel3 2  1.83 2.08 37.3 1.88  2.13 22.4 
female 
 
(1.67–2.26) (1.79–2.39) (31.8–52.9) (1.42–2.34) (1.80–2.96) (13.5–29.7) 
Camel3  2 2.33 2.2 14.4 2.11 2.17 16 
male 
 
(1.52–3.83) (1.54–3.24) (11.0–19.3) (1.50–4.20) (1.70–4.04) (12.9–22.4) 
Elephant4 2.2  5 4.6 77.35 5.5 6.6 123.65 
  
(3.7–7.6) (3.2–5.8) (51.26–132.46) (4.7–7.3) (4.4–8.1) (86.67–194.81) 
Calf5 3 0.42 ± 0.09 2.67 ± 0.79 9.94 ± 1.09 0.42 ± 0.08 1.69 ± 0.25 9.49 ± 0.84 
Llama6 4.4  5.49 ± 1.27 7.72 ± 1.56 168.9 ± 22.4 5.41 ± 0.94 7.56 ± 1.13 176.4 ± 25.5 
Sheep7 3 0.63 ± 0.05 0.64 ± 0.04 5.82 ± 0.45 0.63 ± 0.05 0.77 ± 0.1 10.54 ± 0.92 
1Arifah et al., 2003; 2Verde et al., 2001; 3Al Katheeri et al., 2000; 4Hunter et al., 2003; 5Landoni et al., 
1995b; 6Navarre et al., 2001; 7Arifah et al., 2001.  
 
After oral administration of racemic ketoprofen, absorption is rapid but bioavailability varies 
between animal species. In the cat (Lees et al., 2003), dog (Schmitt and Guentert, 1990), elephant 
(Hunter et al., 2003) and rat (Jamali and Brocks, 1990), bioavailability is high, whereas in horses it 
is extremely low (Landoni and Lees, 1995c). Ketoprofen is metabolised by glucuronidation and 
mainly excreted in urine (Jamali and Brocks, 1990). Enterohepatic circulation of ketoprofen has 
been suggested in dogs and rats, which mainly eliminate ketoprofen into bile (Yasui et al., 1996; 
Granero and Amidon, 2008).  
 
The inversion rate from R-ketoprofen to S-ketoprofen varies between species. In the dog, 
hamster and rat, the rate of inverted R-enantiomer was significantly above 50% (Aberg et al., 1995), 
whereas in the cat (Castro et al., 2000), calf (Landoni and Lees, 1995c), mouse (Aberg et al., 1995), 
gerbil (Aberg et al., 1995), rabbit (Aberg et al., 1995), monkey (Aberg et al., 1995),  dairy cow 
(Igarza et al., 2002) and guinea pig (Aberg et al., 1995) the level of inversion was limited. In dairy 
cows, the percentage of inversion differed according to the physiological status, being higher in 
early lactation than during the dry period (Igarza et al., 2002). The extent of inversion is not 
affected by the dose rate (Menzel et al., 1994; Geisslinger et al., 1995). Administration of racemic 
ketoprofen instead of a pure enantiomer may have an influence on the enantiomeric plasma 
concentration ratio. In mice the S-ketoprofen/total ketoprofen ratio decreased after administration of 
racemic ketoprofen, although the inversion rate was above 40% after administration of pure R-
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ketoprofen (Aberg et al., 1995). In calves no differences were detected between disposition curves 
of enantiomers after administration of racemic ketoprofen, however inversion rate of 30 % has been 
reported after administration of pure R-ketoprofen (Landoni et al., 1995b; Landoni and Lees, 
1995b).   
 
 
5.1.4. Pharmacodynamics of ketoprofen 
 
The primary mechanism of action of ketoprofen is the inhibition of COX, thereby blocking 
prostaglandin biosynthesis from arachidonic acid (Vane, 1971). COX exits in two isoforms, COX-1 
and COX-2, both being targets of ketoprofen and other NSAIDs. Pro-inflammatory prostaglandins 
have an important role in inflammation by inducing fever and hyperalgesia, and mediating 
inflammatory swelling and vasodilatation, thus provoking the cardinal signs of inflammation: 
redness, swelling, heat, pain and loss of function (Diez-Dacal and Perez-Sala, 2010). They 
synergise with mediators such as histamine and bradykinin, which increases permeability. 
Pyrogenic prostaglandins are produced in the hypothalamus and released by bacterial pyrogen 
stimulation. Prostaglandins do not directly stimulate nociceptors, but they enhance nociceptive 
stimuli produced by other mediators, including serotonin, bradykinin and histamine (Lees et al., 
2004). This phenomenon, which increases sensitivity to pain, is called hyperalgesia. Prostaglandins 
are also involved in the allodynia process, in which a stimulus that is not normally painful becomes 
painful in damaged tissue (Hersh et al., 2000). Ketoprofen also inhibits lipoxynase enzyme, which 
blocks bradykinin production (Lees et al., 2004). It crosses the blood-brain barrier and also has 
central analgesic activity (de Beaurepaire et al., 1990; Herrero et al., 1997; Diaz-Reval et al., 2004). 
 
Ketoprofen inhibits both COX enzymes, although it is considered as a COX-1-selective drug 
(Brideau et al., 2001; Streppa et al., 2002). S-ketoprofen is regarded as a more potent COX inhibitor 
than R-ketoprofen (Cabre et al., 1998a; Cabre et al., 1998b). Inhibition of COX-2 is almost 
exclusively attributed to S-ketoprofen (Suesa et al., 1993). 
 
Ketoprofen has central and peripheral activity, which is most probably independent of COX 
inhibition (Carabaza et al., 1996). R-ketoprofen might be responsible for this activity. It has been 
shown that R-ketoprofen has a more potent analgesic effect than S-ketoprofen (Ossipov et al., 2000; 
Pinardi et al., 2001). Intrathecal administration of R-ketoprofen produced a dose-dependent 
antiallodynic effect in rats, while S-ketoprofen did not (Ghezzi et al., 1998). PK/PD modelling of 
the mechanical nociceptive threshold in piglets with kaolin-induced inflammation gave a median 
potency ratio IC50R/IC50S of 0.06, indicating the more potent analgesic action of R-ketoprofen 
(Fosse et al., 2011b). The COX-independent action of R-ketoprofen has not yet been fully clarified. 
 
 
5.1.5. Adverse events 
 
NSAIDs reduce pain and inflammation by blocking COX enzymes that are needed to produce 
prostaglandins and thromboxanes (Vane, 1971). The typical side effects of NSAIDs are also caused 
by this COX inhibition, although some adverse events are not explained by COX inhibition (Little 
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et al., 2007). COX-1, a house-keeping enzyme, is present in most cell types excluding erythrocytes 
and affects prostaglandins, which perform a range of physiological functions such as blood clotting, 
and reno- and gastroprotection (Miller, 2006; Little et al., 2007). COX-2, which is an inducible 
enzyme, is formed at inflammation sites and produces pro-inflammatory prostaglandins. It has been 
found to be present in many tissues, including the gastrointestinal tract as well as neural, 
reproductive and renal tissues, and also has physiological functions (Dinchuk et al., 1995; Miller, 
2006; Little et al., 2007). 
 
 The most frequent side effect of NSAIDs is damage to the gastrointestinal mucosa, which is 
mostly caused by COX-1 inhibition and is independent of the administration route (Wallace, 1997). 
Clinical signs in gastrointestinal irritation and ulceration include depression, anorexia, reduced 
appetite, diarrhoea, vomiting and haematochezia and melena (Stanton and Bright, 1989; Hinton et 
al., 2002). Both COX isoforms are constitutively present in the kidneys (Miller, 2006), and 
inhibition of either COX-1 or COX-2 may therefore result in kidney failure (Lascelles et al., 2005). 
Dehydration, hypovolemia and geriatric age are prediposable factors for renal side effects (Khan et 
al., 1998). Hepatotoxicity may be related to the inhibition of either COX isoform (Carrillo-Jimenez 
and Nurnberger, 2000; Chitturi and George, 2002). Heart-related adverse effects in humans, such as 
heart failure, myocardial infarction and stroke, appear to be largely dependent on COX-2 inhibition 
(Grosser et al., 2010). COX-1 inhibits thromboxane production, which may lead to prolonged 
bleeding, whereas selective COX-2 inhibition may increase the risk of thrombogenesis by 
decreasing prostaglandin-derived vasodilatation and antiaggregation (Miller, 2006) .   
 
NSAIDs differ in their selectivity for COX-isoforms, i.e. how much they affect COX-1 relative 
to COX-2 (Lees et al., 2004). This selectivity does not affect the efficacy of the drug, but it does 
affect the prevalence of adverse events, as gastrointestinal irritation is the most frequent side effect 
(Lascelles et al., 2005). NSAIDs with long half-lives or a slow-release formulation as well as high 
dose rates are associated with a greater risk of upper gastrointestinal bleeding (Masso Gonzalez et 
al., 2010).  
 
Reported adverse effects caused by ketoprofen administration at normal treatment dose levels 
include gastroentero irritation and ulcers, a prolonged bleeding and clotting time, renal disorders 
and photosensitivity (Cabre et al., 1998a; Jerussi et al., 1998; Narita et al., 2005; Luna et al., 2007; 
Devleeschouwer et al., 2008). Most reports of side effects have been from humans, dogs or small 
laboratory animals. In humans, the estimated relative risk for gastrointestinal bleeding or 
perforation after ketoprofen use is 5.4 times higher compared to non-use (Masso Gonzalez et al., 
2010). In anaesthetized piglets, ketoprofen significantly decreased the urinary flow, glomerular 
filtration rate and renal blood flow (Junot et al., 2008). Patients with end-stage renal disease have 
been reported to display selective accumulation of S-ketoprofen after administration of racemic 
ketoprofen (Grubb et al., 1999). Administration of racemic ketoprofen in rats caused more gastric 
toxicity than administration of each enantiomer alone (Alarcon de la Lastra et al., 2002). As gastric 
toxicity caused by the racemate was more than additive, it was suggested that the remaining R-
ketoprofen, which is not inverted, may enhance the gastric toxicity of S-ketoprofen when 
administered as a racemate (Cabre et al., 1998a; Alarcon de la Lastra et al., 2002).  
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Oral administration of indomethacin, aspirin and naproxen for 10 days caused gastroduodenal 
ulcers in pigs (Rainsford et al., 2003). Significant blood loss associated with the appearance of 
gastric ulcers was only evident in pigs administered aspirin. Indomethacin also produced ulcers in 
the caecum. Ulcers caused by NSAIDs are located on the glandular part of the stomach. Gastric 
ulcers affecting the mucosa of the oesophageal part of the stomach are common in pigs (Robertson 
et al., 2002; Swaby and Gregory, 2012). In the UK, 80% of pigs examined after slaughter had 
gastric ulcers and in 6.4% the ulcers were graded as severe (Swaby and Gregory, 2012). Ulceration 
of the pars oesophagea is a multifactorial condition and has several predisposing factors such as 
feeding, infections and stress (Doster, 2000). Clinically, it is impossible to distinguish between 
ulcers in the oesophageal and the glandular area. 
 
A therapeutic dose of 3 mg/kg of racemic ketoprofen administered iv for 5 consecutive days was 
well tolerated in calves (Singh et al., 2009). Gastrointestinal side effects tended to occur in dogs 
administered ketoprofen for 30 days, although the lesions healed after administration ceased and 
were not therefore clinically important in healthy dogs (Narita et al., 2005). Horses showed no 
clinical side effects during ketoprofen administration at a dose of 2.2 mg/kg three times a day for 
twelve days (MacAllister et al., 1993). However, post-mortem examination revealed lesions in the 
glandular part of the stomach. In children, oral ketoprofen is well tolerated when administered up to 
three weeks (Kokki, 2010).  
 
Ketoprofen is a weak acid and it may cause local irritation of the gastric mucosa when 
administered orally (Boothe, 2001). After intramuscular administration to cows it caused no clinical 
signs of pain, and only mild tissue irritation was detected (Pyörälä, 1999).  
 
 
5.2 Endotoxemia in pigs 
 
Postpartum dysgalactia syndrome, typically occurring within three days after farrowing, is an 
important cause of endotoxemia in pigs. Endotoxins are lipopolysaccharides that are major 
compounds of the outer membrane of Gram-negative bacteria. They are released from the cell wall 
during rapid bacterial growth and after lysis. Endotoxins have either a direct or indirect influence on 
multiple organs of the host animal. Their toxic effects include fever, dysfunctions in circulation and 
coagulation, hypoglycaemia and leucopoenia, hypotension and vascular shock, and the activation of 
acute inflammatory reactions (Mayeux, 1997). Many of these effects are not actually caused by 
endotoxins directly, but by overreaction of host immune response. Endotoxins entering the 
circulation are transferred to cell-surface receptors, which primarily exist on mononuclear 
phagocytes. The sensitivity of cells to endotoxin increases and leads to the production of 
proinflammatory mediators. They are responsible for many pathophysiological reactions of 
endotoxemia. For this reason, the severity of the clinical illness is determined by the phagocyte 
response against endotoxins (Moore and Barton, 2003). Pigs challenged with E. coli endotoxin 
developed typical clinical signs such as an increased rectal temperature, anorexia, depression, 
lethargy, hypogalactia, agalactia, vomiting, diarrhoea, firmness and warmth of the udder, 
incoordination, coma and death (Elmore et al., 1978; Liggett et al., 1986). As endotoxins induce an 
increase in prostaglandin and thromboxane levels in the plasma in pigs, the beneficial effects of 
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NSAIDs in the treatment of induced endotoxic shock in pigs have been shown for several drugs, 
including indomethasin (Olson et al., 1985), flunixin meglumin (Olson et al., 1985), flubiprofen 
(Schrauwen et al., 1983), meloxicam (Friton et al., 2006), ketoprofen (Salichs et al., 2012) and 
ibuprofen (Fink et al., 1989). They increase survival and alleviate clinical signs caused by 
endotoxins.  
 
The incidence of PDS varies between regions and individual herds, the average being 
approximately 10% (Backstrom, 1973; Threlfall and Martin, 1973; Backstrom et al., 1984; Thorup, 
2000; Papadopoulos et al., 2010). Regardless of the organ systems primarily involved (mammary 
gland, uterus, urinary tract), the major pathophysiological aspect is bacterial endotoxemia, usually 
caused by E. coli (Reiner et al., 2009). The clinical signs are variable depending on the organs 
involved. Endotoxemia is usually associated with some or all of the following signs: mastitis, 
metritis, cystitis, anorexia, pyrexia and hypogalactia or agalactia (Hirsch et al., 2003; Reiner et al., 
2009). Diseased sows seldom die unless severe endotoxemia occurs, but piglets of diseased sows 
are affected early during the course of the disease. Agalactia or hypolactia caused by endotoxins 
suppressing prolactin production may lead to starvation of newborn piglets (Smith and Wagner, 
1984). The incidence of diarrhoea in piglets of PDS-treated sows increases (Thorup, 2000). Major 
economic losses are due to the increased death rates and decreased growth rates of the piglets. A 
lack of good hygiene, restricted movement and inadequate water and food intake are predisposing 
factors for coliform mastitis. The transferral of sows to farrowing unit at least one week before the 
expected farrowing date, allowance of sows to farrow naturally and frequent supervision of 
farrowing reduce the risk of PDS (Papadopoulos et al., 2010).     
 
 
5.3 Non-infectious lameness in sows and gilts 
 
Lameness is a common problem among sows and gilts. It often leads to poor animal welfare and 
economic losses because of unplanned removals (Chagnon et al., 1991). Lame sows have a higher 
risk of removal from the herd than non-lame sows, and they are removed at a younger age than 
sows removed for other reasons (D'Allaire et al., 1987; Anil et al., 2009). Locomotor disorders have 
been the most common reason for culling sows in Denmark (Kirk et al., 2005) and Sweden 
(Engblom et al., 2008). In Finland, 9% of loose-housed sows and gilts were reported to be lame 
(Heinonen et al., 2006). The most common reason for lameness is osteochondrosis/osteoarthrosis 
(Dewey et al., 1993; Heinonen et al., 2006). Gilts have a higher risk of becoming lame than older 
sows (Chagnon et al., 1991). Lameness is a clinical symptom of potential painful locomotor 
disorders, and pain may also lead to other problems. Food consumption decreases when sows are in 
pain, and milk production is therefore diminished and piglet mortality increases (Chen Cong Ying 
et al., 2008). A lame sow is at a higher risk of crushing piglets (Hill, 1990). The number of pigs 
born alive is lower in lame sows than in sound ones (Anil et al., 2009).  
 
The prevention of problems is better than their cure, and it is ethically more acceptable. 
Management factors have a major influence on the incidence of lameness at the farm level 
(Heinonen et al., 2006). The risk of abnormal gait has been reported to increase on slatted floors 
compared with solid floors (Heinonen et al., 2006; Kilbride et al., 2009). The influence of floor type 
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on foot lesions and traumatic disorders is probably greater than on osteocondrosis (Brennan and 
Aherne, 1987). However, although the risk of lameness can be reduced by good management and 
preventive actions, it cannot be totally eliminated. Early intervention and medication of sick 
animals is important, both for medical and animal welfare reasons. NSAIDs are indicated in the 
treatment of lameness, not just for pain alleviation, but also for their anti-inflammatory actions. 
Meloxicam alleviated pain caused by non-infectious locomotor disorder and improved feed intake 
in lame pigs (Friton et al., 2003). It was administered as a single dose 0.4 mg/kg im and treatment 
was optionally repeated on the next day. Ketoprofen, particularly S-ketoprofen, has been reported to 
reduce interleukin-1β-induced cartilage destruction in vitro and thus to show activity against 
cartilaginous degradation (Panico et al., 2005). 
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6. AIMS OF THE STUDY 
The aim of this thesis research was to investigate the enantiospecific plasma concentrations and 
efficacy of racemic ketoprofen after oral administration in pigs. The specific aims of the study were 
as follows: 
 
1. To determine the plasma concentrations of S- and R-ketoprofen and relative 
bioavailability of both enantiomers after oral and intramuscular routes of administration of racemic 
ketoprofen in pigs; 
 
2. To assess the bioequivalence of racemic ketoprofen after oral and intramuscular 
administration; 
 
3. To determine the effective oral dose of racemic ketoprofen for treating induced 
endotoxemia in pigs; 
 
4. To examine the efficacy and compare two doses of orally administered racemic 
ketoprofen in the treatment of clinical lameness caused by spontaneous non-infectious 
musculoskeletal disorders in sows and gilts.   
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7. MATERIALS AND METHODS 
7.1 Study design 
 
Studies I and II were performed as randomized crossover studies, each pig receiving ketoprofen 
either four times (study I) or two times (study II). The washout period was a minimum of six days 
between the treatments.  
 
Study III was a blinded, placebo-controlled and randomized experimental trial. 
 
Study IV was conducted as a randomized, double-blinded, placebo-controlled clinical field trial 
in ten privately owned farms in southern Finland.  
 
All the studies were in compliance with current national ethical regulations.  
 
 
7.2 Animals and clinical examinations  
 
7.2.1. Animals 
 
Eight crossbred pigs, mean ± SD weight 51.8 ± 8.4 kg at the beginning of the study, 77.9 ± 9.9 
kg at the end of the study, were selected for study I. In study II, eleven crossbred pigs, 5 females 
and 6 barrows, were used. They were 9–13 weeks old at the beginning and their mean body weights 
± SD were 36.5 ± 2.8 kg at the beginning of the trial and 42.6 ± 3.2 kg at the end.  For study III, 40 
crossbred pigs approximately 10 weeks of age and weighting 21–35 kg were purchased. 
 
In study IV, a total of 1955 sows and gilts (30–168 animals per herd) were included in the first 
stage of the study. In the small herds, numbering less than 500 sows, all eligible loose-housed sows 
and gilts were examined for signs of lameness. In units with more than 500 sows, the owner 
presented animals eligible for inclusion according to the instructions of the investigators. In these 
large herds, the maximum number of animals that could be inspected within one day (average of 
104 sows) limited the number of animals included in the study. Lactating sows and sows pregnant 
for > 100 days were excluded. A total of 282 animals with abnormal movements were selected for 
individual examination, and 162 of these were assessed to have a lameness score ≥ 2. Fourteen 
animals were excluded after clinical examination for one or more of the following reasons: 
fractures, infected wounds on the legs, body temperature > 39.5 ºC or any other concurrent disease. 
In addition, seven animals were excluded due to protocol violation. A total of 141 animals, 114 
sows and 27 gilts, were included in the final analysis. The number of animals varied between the 
study farms from 5 to 31.  One healthy control animal was selected for each lame study animal. The 
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control animals were examined and sampled in the same manner as the lame animals, but they 
received no treatment. 
 
The animals included in the studies had not received NSAIDs, systemic antibiotics or systemic 
glucocorticosteroids within 14 days before the start of the trials. 
 
 
7.2.2. Housing and management 
 
In the experimental studies (I, II and III), pigs were housed individually in pens (studies I and II) 
or in groups of ten, with the pigs of each phase in the same pen (study III). They were fed twice 
daily with a standard commercial feed with no antimicrobials. Water was offered ad libitum. In the 
field study (IV), the animals remained at the farm under the care and supervision of their owners 
during the study. Feeding and other husbandry practices remained unchanged during the trial. 
 
 
7.2.3. Clinical examinations 
 
The health status of the study animals was assessed on the basis of clinical examination, 
haematology and blood chemistry prior to the study procedures and before each drug administration 
in studies I and II.  
 
In study III, the pigs were clinically observed by the same person throughout the study. The 
clinical examinations were performed on days -3, -2, -1, 0 (just before injection of endotoxin) and at 
0.5, 1, 2, 4, 6, 8, 10 and 24 hours after the challenge. The general behaviour, respiratory rate and 
locomotion were scored (Table 3). The sum of these scores was calculated to form a total clinical 
score. Rectal temperature was measured using controlled thermometers. 
 
In the first stage of study IV, the investigators evaluated the movement of pigs in groups for 2–5 
min in their own pens. Some animals, whose movements could not be adequately observed in the 
pen, were examined on the gangway. All animals with abnormal movements were selected for 
individual examination. Two investigators independently assessed their lameness using a five-grade 
scoring table (Table 4) while the animals walked on a hard, solid floor for at least 10 m. Animals 
with a lameness score ≥ 2 assessed as identical by both investigators independently were included 
in the study. Secondly, each study animal underwent a thorough clinical examination. The lame leg 
was inspected and palpated. Rectal temperature was measured with a digital thermometer. The 
weight (kg) of the animals was calculated using the following formula: circumference2 (cm) x 
length (cm) / 13 781 (Savage, 2004). The parity number was recorded from the farm data. On day 5, 
the last medication day, the study animals were re-examined a second time in the same way as 
described above.  
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Table 3. The scoring system used to assess the general behaviour, respiratory rate and 
locomotion in pigs challenged with E. coli endotoxin. 
 
Score General behaviour Respiratory rate Locomotion 
 
0 Normal  Normal  Normal 
1 Slightly depressed Increased  Slight incoordination 
and/or reluctance to move 
2 Highly depressed Laboured  Marked ataxia 
3 Comatose  Dead  Dead 
4 Dead  -  - 
 
 
 
Table 4. Lameness scoring system used to assess lameness in sows and gilts. 
Score Lameness Clinical signs 
 
 
0 None No lameness 
1 Minimal Stiff, ataxic or swaying gait, shortened stride 
2 Slight Limp visible, but animal unconcerned and exercises normally 
3 Moderate Obvious limp present all the time (with head bobbing), 
  animal having some difficulty with exercise, moderate 
  kyphotic posture 
4 Severe Animal barely weight bearing/not weight bearing, severely 
  lame but able to move, severe kyphotic posture 
 
 
7.3 Treatments 
 
7.3.1. Racemic ketoprofen, dose rates and administration routes 
 
Racemic ketoprofen was administered via either the parenteral or per oral route (Table 5). All 
treatments in studies I to III were administered as a single dose, whereas the duration of the 
medication in study IV was five consecutive days. 
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Table 5. Racemic ketoprofen products used, routes of administration and dose rates. 
 
Study Drug Route of Dose (mg/kg) 
    administration   
I Romefen1 iv, im 3 
I Dolovet2 po 3 & 6 
II Romefen im 3 
II Ketovet3 po 4 
III Ketovet po 0.5, 1, 2 & 4 
IV Ketovet po 2 & 4 
1Merial, Lyon, France. 2 Vetcare, Salo, Finland. 3 Galena, Kuopio, Finland. 
 
 
 The ear vein of the other ear from that used in blood sampling was used for iv administration. 
The injection site for im injection was the muscle on the right side of the neck. The ketoprofen 
powder was mixed with 40 mL of tap water and administered via a stomach tube for the oral route 
in studies I and II. The tube was flushed with 50 mL water before removal. In study III, ketoprofen 
powder was mixed with tap water at various concentrations so as to administer dose rates 0.5 
mg/kg, 1 mg/kg, 2 mg/kg and 4 mg/kg under the same volume of 1 mL/kg. The control group 
received 1 mL/kg of tap water. Prior to administration, the vials containing the formulations were 
coded by a technician who was not involved in the experimental phase of the study. The test 
solutions were administered orally with a 20 mL syringe that was placed into the mouth of the pigs.  
No notable spilling was observed. Two to four mg/kg are referred to as high-dose groups and 0.5–1 
mg/kg as low-dose groups. 
 
In the field study (study IV), Ketovet oral powder was used as the test product for the dose of 4 
mg/kg. The 50:50 mixtures of Ketovet oral powder and placebo were used for the 2 mg/kg dose. 
The placebo contained 14 g maltodextrine and 1 g of carmellose sodium, both of which are 
excipients of Ketovet oral powder. The University Pharmacy of Helsinki manufactured the 2 mg/kg 
mixture and placebo and re-packed and labelled all sachets. The visual appearance of the powder 
and the sachets was identical. The sachets were labelled in an identical manner and numbered with 
consecutive numbers. All pre-numbered sachets were divided randomly into 4 mg/kg and 2 mg/kg 
of ketoprofen, and placebo groups within blocks of six successive numbers. On each farm, a new 
block was used in order to ensure equal allocation of all the test products within the farms. On the 
basis of each animal’s body weight, the correct daily doses were prepared for 5 days and packed 
into an unused plastic bottle with a cover. Before administration, 10 mL of tap water was added to 
the bottle, the mixture was shaken well and drawn into a 20 mL syringe. The treatment was 
administered via the oral route by placing the syringe deeply into the mouth of the animal to 
minimize spilling.   
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7.3.2. Allocation to the treatment groups 
 
The pigs received the treatments in a random order in studies I and II. In study III the pigs were 
allocated to five groups of eight pigs based on weight and in such a way that the average weights 
were similar between the groups. The five groups were then randomly allocated to treatment groups 
A to E. For practical reasons, the study was conducted in four identical phases performed on 
consecutive days, each phase including two pigs from each group.  
 
In the field study (study IV) the sows and gilts included in the study were allocated at random to 
one of the three treatment groups: placebo, ketoprofen 2 mg/kg or ketoprofen 4 mg/kg. Once an 
animal was included in the study, it was given the next available study number from the medication 
block used on that farm.     
 
 
7.3.3. Endotoxin challenge 
 
The pigs were challenged with E. coli endotoxin in study III. A solution of 20 µg/mL endotoxin 
E. coli lipopolysaccharide O55:B5 (Sigma) in physiological saline was prepared just before the 
challenge. The solution was injected intravenously (superficial brachial vein) at a dose rate 4 µg/kg 
body weight one hour before ketoprofen treatment. 
 
 
7.4 Blood sampling 
 
Heparinised tubes were used in studies I, II and III, and serum and EDTA tubes in study IV. 
 
A vinyl tube (inner diameter 1.0 mm; outer diameter 1.5 mm, Sterihealth®, Australia) for 
venous blood sampling was inserted nonsurgically into the ear vein (studies I and II) or cephalic 
vein (study II) before the first sampling. Each pig was placed on its back and a soft rope snare was 
placed around the maxilla to provide restraint during placement of the tubing. The placement area 
was cleaned and disinfected. A 13-gauge catheter (Intraflon2, Vygon, Ecouen, France) was inserted 
into the auricular vein or cephalic vein, and approximately 50 cm of vinyl tube was threaded 
through the catheter into the vein. The 13-gauge catheter was removed, and a blunted, 18-gauge 
needle hub was inserted into the end of the vinyl tubing. A stopper was then inserted into the needle 
hub to prevent backflow. The vinyl tubing was filled with heparinised saline (0.9% NaCl) solution 
(5 U/mL). To prevent contamination with saline, the first 2 mL drawn up was discarded and the 
sample was taken with another unused 10 mL syringe. Blood samples were collected before each 
treatment, and then 2, 5, 10, 15, 30 and 45 minutes and 1, 2, 3, 4, 6, 8, 12, 24 and 48 hours after iv 
administration of ketoprofen, and 15, 30 and 45 minutes and 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48 
hours after po and im ketoprofen administration in study I. In study II, blood samples were collected 
before each treatment, and then 30 and 45 minutes and 1, 1.25, 1.5, 1.75, 2, 4, 6, 8, 10, 12 and 24 
hours after po and im administration of ketoprofen.  
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In study III the blood samples were collected from the vena cava before and 0.5, 1, 2, 4, 8, 10 
and 24 hours after the endotoxin challenge. In the field study (IV), the samples were taken from the 
saphenous or tail vein on days 0 and 5.   
 
 
7.5 Laboratory analysis 
 
The serum (study IV) and plasma (studies I, II and III) samples were centrifuged and 
immediately frozen and stored at -18 °C or lower until analysed.  
 
 
7.5.1. Total ketoprofen plasma concentration analysis 
 
In study I, total plasma concentrations of racemic ketoprofen were determined by HPLC 
analysis according to the method described by Owen et al. (1987) with slight modifications. 
Determinations were conducted on 4 samples in parallel. The HPLC system was equipped with a 
piston pump Waters 501 (Waters Corp, Milford, MA, USA), Waters 717 autosampler (Waters Corp, 
Milford, MA, USA), Waters 486 tunable absorbance UV detector (Waters Corp, Milford, MA, 
USA) and Millenium 32 chromatography manager workstation (Waters Corp, Milford, MA, USA). 
Sample separation was conducted on a 4.6 X 150 mm column packed with 5 µm of reversed-phase 
silica SunFire C18 (Waters Corp, Milford, MA, USA). The flow rate of the isocratic mobile phase, 
which consisted of acetonitrile and 0.03% phosphoric acid (1:1), was 1.5 mL/min. The analytic 
wavelength was 254 nm. The method was validated as recommended for bioanalytic assays (Shah 
et al., 2000) by analysing 6 parallel plasma samples spiked with ketoprofen. The standard curve was 
found to be linear (r2 > 0.998) for the concentration range of 0.36 to 50 mg/L. The limit of 
quantification was 0.36 mg/L.  
 
In study III the assay method was a modification of that previously described by Upton (1980). 
The procedure involved the liquid-liquid extraction of ketoprofen from plasma and reversed-phase 
chromatography with UV detection. The chromatographic system consisted of an Agilent 1100 
HPLC with an Agilent ChemStation data system. The mobile phase was a mixture of acetonitrile 
and 0.05 M potassium dihydrogen phosphate, pH 4.4–4.6 (65:35, v/v). A mixture of 0.5 mL of 
plasma, an internal standard (ibuprofen, 500 ng) and 250 µL of 1 M phosphate buffer, pH 2, was 
extracted with 4 mL of diethyl ether. After centrifugation, the organic layer was separated and 
evaporated to dryness at 40 ºC under a stream of nitrogen. The dried residue was reconstituted with 
100 µL of the mobile phase and 50 µL was injected onto the HPLC column (Phenomenex Luna 
C18 (2), 250 x 4.6 mm, 5 µm). The effluent was monitored at 275 nm (ketoprofen) and 222 nm 
(ibuprofen) with a flow rate of 1.0 mL/min. Ketoprofen concentrations were quantified using linear 
regression of peak height ratios (ketoprofen/internal standard) vs. concentration. The calibration 
curve was linear from 0.1 to 7.5 µg/mL, and the lower limit of quantification was 0.1 µg/mL. 
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7.5.2. Enantiospecific ketoprofen plasma concentration analysis 
 
Plasma concentrations of ketoprofen enantiomers were separated on a chiral column and 
detected by LC-MS/MS analysis. Organic solvents were of HPLC grade and other chemicals of 
analytical purity. Racemic ketoprofen used for standard curves and spiked samples was obtained 
from USP U.S. Pharmacopeia (Rockville, MD, USA) and racemic ketoprofen-d4 from Qmx 
Laboratories (Thaxted Essex, UK). Optically active S-ketoprofen was purchased from Aldrich 
(St Louis, MO, USA) and was used to identify the elution order of ketoprofen enantiomers. 
Appropriate standard solutions were prepared by dilution with methanol. For ketoprofen analysis, 
plasma samples were centrifuged (4000 rpm, 5 min) and a portion of a sample  (0.5 ml) was diluted 
with  ammonia (4%, 0.5 ml), subsequently followed by solid phase extraction  (Oasis MAX, 1cc, 30 
mg, Waters). Before sample loading, the cartridge was conditioned with methanol (1 ml) and water 
(1 ml). The cartridge was washed with ammonia (5%) in water (1 ml), methanol (1 ml) and formic 
acid (2%) in methanol/water (45/55, v/v, 1 ml). The analytes were eluted with formic acid (2%) in 
methanol/water (90/10, v/v, 1 ml). The solvent was evaporated to dryness under a stream of 
nitrogen at 45 °C and redissolved in the mobile phase (250 µl). An aliquot of a sample (10 µl) was 
injected into the LC-MS/MS. 
 
Ketoprofen enantiomers were separated on a chiral column (Chirobiotic R, 15 cm x 2.1 mm, 5 
µm, Supelco, Bellefonte, USA) protected with a guard column (C 18, 4x 2.0 mm, Phenomenex) 
using ammonium acetate buffer (20 mM, pH 5.6 adjusted with formic acid) in 30% methanol. The 
flow rate was 0.2 ml/min and the column temperature was set at 18 °C.  
 
The LC-MS/MS instrumentation consisted of a Waters Alliance 2695 Separations Module 
(Waters, Milford, MA, USA) and a MicroMass Quattro Micro triple quadrupole tandem mass 
spectrometer (MicroMass Ltd, Manchester, UK) operated in the negative ion mode. The mass 
spectrometric parameters were: capillary voltage 3.0 kV; source temperature 120 °C; desolvation 
temperature 300 °C; N2 cone gas flow 15 L/h and N2 desolvation gas flow 500 L/h. Argon was used 
as a collision gas. The multiple reaction monitoring mode was used for monitoring ion transitions, 
which were m/z 253 for the deprotonated molecular ion [M-H]- and m/z 209 for the product ion. 
The transition m/z 257 to 213 was monitored for the racemic ketoprofen-d4, which was used as an 
internal standard. Peak integration and calibration were performed with QuanLynx software 
(MassLynx 4.0, Waters). 
 
The matrix-matched calibration curve was found to be linear over the selected concentration 
range of 4–7000 ng/ml for each enantiomer by a weighted (1/x2) least-squares linear regression 
model. Method validation was performed in the lower concentration range of 4–60 ng/ml.  
Recovery and precision (repeatability and within-laboratory reproducibility) were measured by 
spiking six blank plasma samples at levels of 5, 15 and 50 ng/ml for both enantiomers on three 
different days (N = 18 for all concentrations). Recoveries varied between 94–109% for S-
ketoprofen and 91–96% for R-ketoprofen. The coefficients of variation of repeatability (CVr %) 
were less than 8.7% for S-ketoprofen and less than 9.8% for R-ketoprofen, while the coefficients of 
variation of within-laboratory reproducibility (CVwlR %) were less than 11.2% and 10.2%, 
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respectively. The limit of detection was 2 ng/ml in plasma for both enantiomers evaluated from the 
lowest spiking level (5 ng/ml), which is considered as the limit of quantification of the method. 
 
 
7.5.3. Analyses of thromboxane B2 and haptoglobin plasma concentrations, and haematological 
parameters 
 
Prior to immunoassay, TXB2 extraction was performed in order to improve the quality of dosage 
by eliminating potential interfering compounds contained in plasmas. The extraction was performed 
by using the plateprep 96-well vacuum manifold starter kit (Sigma, France). TXB2 was determined 
by an ELISA technique kit (Thromboxane B2 Enzyme Immunoassay, Assay Designs, USA) at the C 
RIS Pharma Laboratory (Saint Malo, France). Each sample was tested in simplicate, but standards 
were assayed in duplicate. The absorbance was read at 405 nm with a Multiskan EX apparatus 
(Thermo Labsystems, France), the reference wavelength being 570 nm. The TXB2 concentration 
was expressed in pg/ml. 
 
Haptoglobin was measured by using the haemoglobin-binding assay for bovine (Makimura and 
Suzuki, 1982), with slight modifications in which tetramethylbenzidine (0.06 mg/ml) was used as a 
substrate (Alsemgeest et al., 1994) and the assay was adapted for microtitration plate use. Optical 
densities of the wells were read at 450 nm using a spectrophotometer (Multiskan MS, Labsystems 
Oy). The assay was calibrated using a reference porcine acute phase serum sample provided by the 
European Commission Directorate General Research Concerted Action Group (project number 
QLK5-CT-1999-0153). Haemolysis of the samples was estimated visually using a 3-grade scoring.   
 
The haemoglobin concentration, packed cell volume, leukocyte and erythrocyte counts (study 
IV) were analysed using a Vet ABC Animal Blood Counter (ABX Diagnostics). 
 
 
7.6 Pharmacokinetic parameters 
 
Pharmacokinetic parameters were calculated by using Kinetica software (Thermo Electron Corp, 
Waltham, USA). The non-compartment analysis was applied for R- and S-ketoprofen plasma 
disposition curves. The AUC was calculated by use of the trapezoidal method. In each case, AUC0-
12 or AUC0-24, in studies I and II, respectively, was >80% of the calculated AUC0-∞. Values for Cmax 
and Tmax were directly determined from individual time vs. plasma concentration curves. The t1/2 
was calculated as 0.693/β, in which β is the elimination rate constant. The MRT was calculated as 
the area under the first-moment curve from time 0 to infinity divided by AUC0-∞. The MAT was 
calculated as MRTextravascular –MRTiv, where MRTextravascular is the MRT after po or im administration 
and MRTiv is the MRT after iv administration. Values for Vd were calculated by use of the area 
method as Vd = (dose/[AUC0-∞ X β]), and CL was calculated as dose/AUC0-∞; values for Vd and CL 
was standardized per kilogram of body weight. The relative bioavailability was determined for S 
and R-ketoprofen by calculating (AUCpo/ AUCim) (Dim/Dpo)*100%. The im route was used as a 
reference. 
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7.7 Evaluation of efficacy in the treatment of lameness 
 
The efficacy of the treatment was assessed according to the lameness score on day 5. A 
lameness score of 0 represented excellent efficacy and a lameness score of 1 represented good 
efficacy. If the lameness score decreased from 4 to 3, from 3 to 2 or from 4 to 2, the efficacy of the 
treatment was considered fair. No improvement or deterioration in the lameness score was 
considered as poor efficacy. Excellent and good efficacy scores were considered as a successful 
outcome for the treatment. 
 
 
7.8 Statistical analysis 
 
Pharmacokinetic parameters obtained for S- and R-ketoprofen within administration groups 
were compared by use of the paired Student’s t-test (AUC, Cmax, T1/2, MRT, Frel) or Wilcoxon 
matched-pairs rank test (Tmax). As ketoprofen pharmacokinetics is linear, the dose was normalized 
(AUCnorm=(Dim/Dpo) x AUCpo) when AUCs were statistically compared between administration 
groups. 
 
To assess bioequivalence, the 90% CI was calculated for AUC0-12 in study I, and for Cmax, all of 
which were logarithmically transformed. The 90% CI should be within an acceptance interval of 
0.80 to 1.25 (EMEA, 2001). 
 
Statistical analyses in study III were performed using commercial software (SAS System for 
Windows, version 9.3). Repeated measures analyses of covariance (RM ANCOVA) models were 
constructed for rectal temperatures and TXB2 values. The models included treatment group, time, 
baseline rectal temperature/TXB2 value, sex and an interaction term between the treatment group 
and time as fixed effects, and the pig as the only random effect. Compound symmetry was used as 
the covariance structure. Based on the parameters of the fitted models, comparisons between 
treatment groups over time periods and at 1 hour were conducted together with within treatment 
group comparisons between time points (comparisons against baseline). Dunnett’s test was used for 
the pairwise comparisons against the baseline. 
 
In addition, a similar model where the four ketoprofen groups were put together was constructed 
for TXB2 to achieve a comparison between pigs that received the drug and pigs treated with 
placebo. The difference between the two groups was calculated over time from the 2-hour time 
point forward, as the drug was given at 1 hour. A subject-specific cumulative logit model was 
constructed for the total clinical score. The model included the main effects for the treatment group 
and time as fixed effects and the pig as the random effect. No other terms could be inserted into the 
model as fixed effects because there were very few observations in the higher categories of the total 
clinical score. A model where ketoprofen groups were put together was also constructed for total 
clinical score similarly, as with TXB2. In this model, an interaction term between treatment group 
and time and sex was inserted into the model as a fixed effect. The differences between groups in 
the total clinical score were quantified with odds ratios and their 95% confidence intervals.  The 
median and range of total ketoprofen plasma concentrations one hour after ketoprofen treatment 
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were calculated. Correlations between the plasma concentration of TXB2 at 60 min post-
administration and the rectal temperature and clinical signs were compared with Spearman’s rho 
test. 
 
In the field study (IV), statistical analyses were performed and tables produced using SAS 
software (SAS Institute, version 8.2). Blood parameters were analysed with Stata Intercooler 
version 10.0. The statistical unit was the sow.  Treatment groups were compared using the Cochran-
Mantel-Haenszel test with respect to the lameness score on day 0, parity number, change in 
lameness score from day 0 to day 5, treatment success in relation to the parity number and the 
efficacy of the treatment.  Treatment success stratified by farm, parity and lameness score on day 0 
was compared using a stratified CMH test. A logistic model was used to evaluate the interaction 
between slatted floor housing and the treatment group (ketoprofen groups were pooled), with 
treatment success as an outcome. Haemoglobin concentrations, PCV, erythrocyte and leukocyte 
counts, and haptoglobin concentrations in the three treatment groups and in the control animals 
were compared using ANOVA.  
 
Descriptive data were presented as the mean values and SD or SEM of groups. For all tests, p < 
0.05 was considered significant. 
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8. RESULTS 
8.1 Ketoprofen plasma concentrations 
 
The peaks corresponding to racemic ketoprofen retention time (study I) were 4 min, and to the 
S- and R-ketoprofen (study II) 7.0 min and 8.4 min, respectively. Representative ion 
chromatograms of porcine plasma spiked with 30 µg/mL for racemic ketoprofen and 200 ng/mL for 
both enantiomers are presented in Figures 1 and 2, respectively. 
 
The mean plasma concentration profiles of total ketoprofen following po, im and iv 
administration, and of S- and R-ketoprofen following po and im administration of racemic 
ketoprofen to healthy pigs (studies I and II) are illustrated in Figures 3 and 4, respectively. The 
plasma S-ketoprofen was above the LOQ for all sampling points after drug administration, except in 
one pig after the po route and three pigs after the im route at 24 hours post-administration. In most 
pigs (seven animals after po administration and nine after im administration), R-ketoprofen was 
above the LOQ for four hours or less. The remaining animals had quantifiable values for up to 24 
hours. The second peak was evident in S-ketoprofen concentrations in plasma in most pigs, and it 
was more obvious after po administration than after im administration. It was not detected in R-
ketoprofen (Figure 5). 
 
In study III, the medians (range) of total ketoprofen plasma concentrations in endotoxin 
challenged pigs one hour after ketoprofen treatment were 0.1 µg/mL (<0.1–1.0), 0.19 µg/mL (<0.1–
1.57), 0.83 µg/mL (<0.1–2.99) and 2.09 µg/mL (0.34–7.87) in the ketoprofen treatment groups 0.5 
mg/kg, 1 mg/kg, 2 mg/kg and 4 mg/kg, respectively.  
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Figure 1. Representative chromatograms of porcine plasma spiked with racemic ketoprofen (30 
µg/mL; A) and a plasma sample obtained from a pig 5 min after administration of racemic 
ketoprofen (3 mg/kg, iv; B). The total ketoprofen concentration in the treated pig was 23.8 
µg/mL. 
Time (min) 
A 
B 
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Figure 2. LC-MS/MS chromatograms of (A) porcine plasma spiked with racemic ketoprofen 
(100 ng/mL for each enantiomer) and (B) the corresponding internal standard (50 ng/mL for 
each enantiomer), and (C) a plasma sample obtained from a pig at 45 minutes after oral 
administration of racemic ketoprofen (4 mg/kg). 
min 
6.00 8.00 10.00 
% 
0 
100 
MRM of 3 channels, ES- 
253.2 > 209.26 
 
E28729  
 (S)
-ktp 
(R)-
ktp 
min 
6.00 8.00 10.00 
% 
0 
100 
MRM of 3 channels,ES- 
257.29 > 213.14 
 
  
 (S)-ktp-d4 
 
(R)-ktp-d4 
min 
% 
0 
100 
MRM of 3 channels,ES- 
253.2 > 209.26 
 
Spiked plasma  
 (S)-
ktp (R)-
ktp 
6.00 8.00 10.00 
C 
A 
B 
 
 
 
 
34 
 
Figure 3. Mean ± SEM total plasma ketoprofen concentrations in 8 pigs after administration of a 
single dose of racemic ketoprofen by various routes of administration. Ketoprofen was 
administered at time 0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Mean ± SEM plasma concentrations of S- and R-enantiomers in 11 pigs after 
administration of single doses of racemic ketoprofen, 3 mg/kg im and 4 mg/kg po. Ketoprofen 
was administered at time 0.   
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Figure 5. Individual plasma S- and R-ketoprofen concentration profiles of two pigs the first two 
hours after PO administration of racemic ketoprofen at dose rate of 4 mg/kg. 
 
 
8.2 Pharmacokinetic parameters 
 
Pharmacokinetic parameters for total plasma ketoprofen, and for plasma S- and R-ketoprofen 
are presented in Tables 6 and 7, respectively. 
 
Bioavailability of total ketoprofen was almost complete after im and po administration. Mean ± 
SD relatively bioavailability (po vs. im administration) of total ketoprofen in study II was 89.2 ± 
3.1%. Frel (%) was 83% ± 20% and 63% ± 23% (p = 0.01) for S-ketoprofen and R-ketoprofen, 
respectively. 
 
Table 6. Pharmacokinetic parameters (mean ± SD) of ketoprofen in pigs (n = 8) after single 
doses of 3 mg/kg po, 6 mg/kg po, 3 mg/kg im and 3 mg/kg iv. 
 
Parameter  3 mg/kg po 6 mg/kg po 3 mg/kg im 3 mg/kg iv  
T½ (h)  3.52 ± 0.90 3.22 ± 0.43 2.95 ± 0.21 2.66 ± 0.50 
MRT (h)  5.54 ± 1.28 5.15 ± 0.86 4.49 ± 0.44 3.40 ± 0.51 
MAT (h)  2.15 ± 1.01 1.75 ± 1.11 1.09 ± 0.35 - 
Tmax (h)   1.25 ± 0.90 1.19 ± 0.46 1.06 ± 0.48 - 
Cmax (μg mL
-1) 5.09 ± 1.41 12.03 ± 4.81 7.62 ± 1.22 - 
AUC0-12 (μg mL
-1 h) 28.3 ± 6.7 63.4 ± 17.6 34.6 ± 6.5 32.4 ± 7.6 
AUC0-∞ (μg mL
-1 h)  32.04 ± 9.20 69.51 ± 19.32  37.14 ± 6.99 33.86 ± 8.45 
F (%)  96.7 ± 27.1 104.9 ± 26.6 114.6 ± 29.9 - 
CL (L h-1 kg-1) - - - 0.094 ± 0.024 
Vd (L/kg)  - - - 0.35 ± 0.09 
 
- = Not determined. 
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Table 7. Mean values (± SD) of pharmacokinetic parameters for ketoprofen after po or im 
administration of a single dose to 11 crossbred pigs.   
  Route of administration  
Parameter po 4 mg/kg im 3 mg/kg  
Cmax (mg/L)                  S-Ketoprofen 7.42 ± 2.35
* 7.32 ± 0.75*  
                                      R-Ketoprofen 2.55 ± 0.99 3.23 ± 0.70  
Tmax (h)                         S-Ketoprofen 1.91 ± 1.65* 1.27 ± 0.45*  
                                      R-Ketoprofen 0.59 ± 0.23 0.65 ± 0.30  
AUC0-∞ ([mg/L]) · h     S-Ketoprofen    47.04 ± 13.41*   44.09 ± 12.87*  
                                      R-Ketoprofen 3.83 ± 1.23 5.16 ± 2.48   
T1/2 (h)                           S-Ketoprofen 3.40 ± 0.91* 2.89 ± 0.85*   
                                      R-Ketoprofen 1.1 ± 0.90 0.75 ± 0.48   
MRT (h)                        S-Ketoprofen 5.55 ± 1.45* 4.91 ± 1.21*   
                                      R-Ketoprofen 1.73 ± 0.92 1.49 ± 0.67   
AUCS/AUCR ratio 12.8 ± 3.17
** 9.2 ± 2.39**   
* Denotes a significant difference (p < 0.05) between S-ketoprofen and R-ketoprofen when 
comparing within administration groups. ** Denotes a significant difference (p < 0.05) between 
administration routes (po versus im). 
 
8.3 Bioequivalence 
 
Equivalence could not be detected for AUC0-12 values of the total ketoprofen plasma 
concentration between 3 mg/kg administered po and iv (90% CI, 0.75 to 1.02), 3 mg/kg 
administered im and iv (90% CI, 0.90 to 1.29), or 3 mg/kg administered po and im (90% CI, 0.66 to 
0.99). Neither was equivalence detected for Cmax of the total ketoprofen plasma concentration 
between 3 mg/kg administered po and im (90% CI, 0.53 to 0.80).   
 
 
8.4 Rectal temperatures and total clinical scores 
 
Mean rectal temperatures and total clinical scores are presented in Figures 6 and 7, respectively. 
The sex had no effect. No differences between pigs were detected in the rectal temperature at 1 hour 
after endotoxin challenge before ketoprofen treatment (p > 0.05). The rectal temperature and the 
total clinical scores were elevated for up to 4 hours after endotoxin exposure in the control group, 
up to 2 hours in two ketoprofen low-dose groups and at 1 hour in two high-dose groups, although 
the differences in the total clinical scores between the groups were minor. The dose rates 2 and 4 
mg/kg reduced rectal temperatures compared to the control group (p = 0.007 and p = 0.027, 
respectively). The overall treatment effect of the mean rectal temperatures was 0.35 ºC and 0.29 ºC 
lower in ketoprofen 2 and 4 mg/kg groups, respectively, than in the control group. Ketoprofen 
treatment significantly lowered the total clinical score compared to the placebo group, although 
when comparing separate dose rates with the control group no significant differences were detected. 
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Figure 6. Effects of oral ketoprofen on the mean ± SEM rectal temperatures in pigs after 
intravenous challenge with E. coli endotoxin. The treatments were administered one hour (T1h) 
after endotoxin challenge (T0h). (n = 40) 
 
 
 
Figure 7. Effects of ketoprofen on the mean ± SEM total clinical score in pigs after intravenous 
challenge with E. coli endotoxin. The treatments were administered one hour (T1h) after 
endotoxin challenge (T0h). (n = 40) 
 
 
8.5 TXB2 plasma concentrations and laboratory analysis 
 
Mean plasma TXB2 concentrations are presented in Figure 8. No significant differences between 
pigs were detected in the TXB2 concentration at 1 hour after endotoxin challenge before ketoprofen 
treatment. The plasma TXB2 concentration was elevated for up to 4 hours after the endotoxin 
challenge in the control group and up to 1 hour in the groups treated with ketoprofen (p < 0.01). 
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Ketoprofen treatment reduced a TXB2 concentration of 1012 pg/mL (95% CI, -1848 to -177) 
between 2 to 10 h post endotoxin challenge compared to the control group (p = 0.02), although no 
significant differences were detected between separate dose rates. Plasma concentrations of TXB2 at 
1 hour correlated significantly with clinical signs (coefficient 0.57), but not with the rectal 
temperature (-0.24).   
 
The haemoglobin and haptoglobin concentrations, packed cell volume, leukocyte and 
erythrocyte counts blood values of the animals in study IV were within the normal range or showed 
only minor changes both before and after ketoprofen medication (Friendship et al., 1984; Heinonen 
et al., 2006).  
 
 
Figure 8. Effects of oral ketoprofen on the mean ± SEM TXB2 concentrations in pigs after 
intravenous challenge with E. coli endotoxin. The treatments were administered one hour (T1h) 
after endotoxin challenge (T0h). (n =40) 
 
 
8.6 Efficacy in the treatment of lameness 
 
The ketoprofen 4 mg/kg group comprised 46 pigs, the ketoprofen 2 mg/kg group 47 pigs, and 
the placebo group 48 pigs. Approximately 20% of each group comprised gilts, 50% sows with a 
parity of one to three, and 30% sows with a parity of four or more (p = 0.91, CMH test). The 
lameness scores of the animals in different treatment groups did not differ in the beginning (day 0) 
of the study (table 8). Mean changes of lameness scores from day 0 to day 5 appear in Table 9, and 
the efficacy of treatment in different groups appears in Table 10. The treatment was considered 
successful for 54.3% of the animals in the ketoprofen 4 mg/kg group, 53.2% of the animals in the 
ketoprofen 2 mg/kg group, and 20.8% of the animals in the placebo group. The difference between 
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both ketoprofen groups and the placebo group was significant (p = 0.001, CMH test stratified by 
farm), but the difference between the two ketoprofen groups was nonsignificant (p = 0.78, CMH 
test stratified by farm). The treatment successes of the three parity groups showed no differences (p 
= 0.21, CMH test stratified by farm). 
 
Fully slatted floors had no direct impact on the success rate (p = 0.43), but the interaction 
between the treatment and slatted floor was significant (p = 0.04, from the logistic regression model 
where the ketoprofen groups were combined). On both of the floor types, the ketoprofen groups had 
higher success rates than the placebo group, but the differences were more pronounced in farms 
with concrete or only partly slatted floors. 
 
 
Table 8. Lameness scoring of 141 lame animals on day 0 
Lameness 
Total 
n (%) Ketoprofen  Ketoprofen  Placebo 
score 
of 
animals 4 mg/kg 2  mg/kg 
     n of animals n of animals n of animals 
2 Slight 81 (57%) 30 27 24 
3 Moderate 58 (41%) 15 20 23 
4 Severe 2 (1%) 1 0 1 
Total 141 46 47 48 
The lameness scores did not differ significantly between the three treatment groups on day 0 (p 
= 0.37). 
 
 
Table 9. Average lameness scores and their mean changes in 141 lame sows and gilts before 
(day 0) and after (day 5) per oral ketoprofen (two dose groups) or placebo treatment for 5 days  
Treatment 
group 
 
Animals 
n  
Mean score on  
day 0 (± SD) 
Mean score on 
day 5 (± SD) 
Mean change 
(± SD) 
Ketoprofen  
4 mg/kg 46 2.37 (0.53) a 1.5 (0.98) a 0.87 (0.98) a 
Ketoprofen  
2 mg/kg 47 2.43 (0.50) a 1.38 (0.97) a 1.0 (1.0) a 
Placebo 48 2.52 (0.55) a 2.08 (0.82) b 0.44 (0.82) b 
a,b Groups with different superscripts within the column differ significantly (p < 0.05). 
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Table 10. Efficacy of treatment of 141 lame sows or gilts in three treatment groups: ketoprofen 4 
mg/kg, 2 mg/kg and placebo orally for 5 days  
Efficacy 
 
Ketoprofen 4 
mg/kg, number (%) of 
animals 
Ketoprofen 2 
mg/kg, number (%) of 
animals 
Placebo 
number (%) of animals 
Excellent 7 (15%) 10 (21%) 2 (4%) 
Good 18 (39%) 15 (32%) 8 (17%) 
Fair 4 (9%) 8 (17%) 10 (21%) 
Poor 17 (37%) 14 (30%) 28 (58%) 
 
 
8.7 Adverse events 
 
All pigs in the study II were euthanized after completing the study, and sent for necropsy. Signs 
of peptic ulcers were found in seven out of eleven animals. All the ulcers were in the glandular part 
of the stomach except in one pig, which had ulcers in the oesophageal area. None of them showed 
clinical signs or any abnormalities in blood values. 
 
In study III, two pigs treated with 1 mg/kg ketoprofen died between 10 and 24 hours after the 
endotoxin challenge. Clinically, one of them had laboured breathing during the first two hours after 
the endotoxin challenge. Otherwise, both pigs were clinically normal when compared to other 
animals in the same group up to 10 hours after the challenge. At 10 hours, their general behaviour 
was depressed and they had marked ataxia. One of the pigs was hypothermic (37 °C), while the 
other had a rectal temperature within the reference range (38.8 °C). Their plasma TXB2 
concentrations remained high, despite ketoprofen treatment. Post-mortem examination of the 
hypothermic pig failed to reveal any macroscopic pathological signs, whereas fatty degeneration of 
the liver and hyperemia of the gastrointestinal tract were observed in the other dead pig. The latter 
could have been at least partially a post-mortem change. Plasma ketoprofen concentrations at one 
hour after its administration were below the limit of quantification and 0.23 µg/ml in the 
hypothermic and normothermic pig, respectively. 
 
In the two other studies (studies I and IV), tolerance of ketoprofen was good, and no adverse 
events were observed. 
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9. DISCUSSION 
Orally administered racemic ketoprofen was shown to be absorbed well and was efficacious in 
the treatment of endotoxemia and lameness in pigs. Clinical tolerance of ketoprofen treatment was 
good and it was easy to administer, even to loose-housed sows. 
  
 
 9.1 Pharmacokinetics of orally administered racemic ketoprofen 
 
The absolute bioavailability of both ketoprofen enantiomers after im administration is suggested 
to be almost complete (Fosse et al., 2011a; Fosse et al., 2011b). After po administration, 
bioavailability is reported to be lower but similar, approximately 85%, for both enantiomers 
(Neirinckx et al., 2011a). The results of our studies are consistent with previous findings; the 
bioavailability of racemic ketoprofen was almost complete in pigs after po and im administration. 
The relative bioavailability of S-ketoprofen after oral administration was significantly higher than 
for R-ketoprofen. Since S-ketoprofen is generally regarded as the eutomer regarding 
cyclooxygenase inhibition, and the terminal half-life of R-ketoprofen is short, in clinical use the 
administration routes at dose rates used in this study could be considered equally effective.  
 
S-ketoprofen was the predominant enantiomer in pig plasma after administration of the 50:50 
racemic drug via both routes, as in most animal species previously studied. Our results agreed with 
other studies in pigs (Larsen et al., 1991; Fosse et al., 2011a; Neirinckx et al., 2011a). The 
pharmacokinetic parameters of both enantiomers after im administration were similar to those 
reported by Fosse (2011a) in young piglets with only minor differences, despite the pigs in our 
study being older than those used in their study. Tmax and AUCS/AUCR ratio after oral 
administration were higher in our study than in the study reported by Neirickx (2011a). The 
ketoprofen product used in that study was an oral solution, which could have been absorbed faster 
than the oral powder we used.  
 
The higher relative bioavailability of S than R ketoprofen in our study suggests that some 
stereoselective absorption and/or first pass metabolism may have occurred. The physicochemical 
properties of the enantiomers are identical and the absorption of ketoprofen is not therefore 
considered stereoselective. Absorption has been regarded as mainly a passive process, but there is 
also some evidence suggesting that ketoprofen may have an active transport pathway across the 
intestinal wall (Foster and Jamali, 1988; Foster et al., 1988a; Foster et al., 1988b; Jamali and 
Brocks, 1990; Aberg et al., 1995; Choi et al., 2006). In rats, 84% of the administered dose of R-
ketoprofen was inverted to S-ketoprofen in the gastrointestinal tract (Foster and Jamali, 1988), 
while an absence of pre-systemic inversion was reported in pigs (Neirinckx et al., 2011b). The 
inversion rate of R-ketoprofen to S-ketoprofen is equally high in rats and pigs (approximately 70%) 
(Aberg et al., 1995; Neirinckx et al., 2011b). Presystemic inversion in the gastrointestinal tract has 
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also been reported in rats after ibuprofen and fenoprofen administration, and was dependent on the 
absorption rate (Berry and Jamali, 1991; Sattari and Jamali, 1994). However, presystemic inversion 
of R-benaxoprofen to S-benaxoprofen detected in gut preparations was weak compared to inversion 
in the liver and kidney (Simmonds et al., 1980; Nakamura and Yamaguchi, 1987). The possible 
faster absorption rate of the oral solution used by Neirinckx (2011a) may have been partially 
responsible for the absence of possible pre-systemic inversion found in their study. In our study, the 
slower absorption rate from the gastro-intestinal tract might have contributed the pre-systemic 
inversion. Ketoprofen solution has reported to reach the maximum plasma concentration earlier 
than the tablet formulation (Stiegler et al., 1995). The racemic ketoprofen used in our studies was an 
oral powder, which was insoluble in water. In the present study, the difference in relative 
bioavailability between enantiomers was smaller, although significant, than that reported in rats 
after po and ip administration (Foster and Jamali, 1988). After ip dosing, the AUCs of both 
enantiomers were similar to those after iv dosing, which would suggest that presystemic inversion 
occurs in the gastrointestinal tract. In our study, fluctuation evident in total plasma ketoprofen 
concentrations was also observed in S-ketoprofen plasma concentrations after po and im 
administration. There was individual variation in the sharpness of the fluctuation in plasma 
concentrations of S-ketoprofen, and the peak was more evident after po administration of 
ketoprofen than after im administration. In most of the pigs, it was clearly evident within two hours 
after per oral ketoprofen administration. It may have been caused by enterohepatic recycling. The 
phenomenon was not detectable for R-ketoprofen. Stereoselective enterohepatic circulation of 
ketoprofen exists at least in rats (Yasui et al., 1996). Yasui et al. (1996) suggested that the 
glucoronide of S-ketoprofen is hydrolyzed more slowly than the glucuronide of R-ketoprofen in the 
intestine. This would lead to a longer mean transit time of S-ketoprofen from the bile duct via the 
intestinal tract and into the systemic circulation, and stereoselective enterohepatic recycling may 
therefore occur. However, the high degree of chiral inversion from S- to R-ketoprofen could also 
explain some fluctuation in the plasma S-ketoprofen concentration, especially as it was more 
evident after po than im administration. 
 
Since the difference in AUC values between enantiomers was significant for po and im 
administration routes, the most probable reason for the lower AUC of R-ketoprofen was the higher 
clearance compared to S-ketoprofen. The enantioselective differences in clearance may be 
attributable to differences in distribution, chiral inversion, hepatic metabolism, renal excretion, or to 
a combination of these factors. The volume of distribution for ketoprofen is low, 0.35 in our study, 
probably due to high protein binding. Enantioselectivity in the binding of ketoprofen to plasma 
proteins has been reported in humans and camels (Dubois et al., 1993, Al Katheeri et al., 2000), 
although contradictory results have also been reported in humans (Lagrange et al., 2000). There 
have been no reports of possible enantioselective protein binding in pigs.  
 
 In our study the terminal half-life and MRT of R-ketoprofen were approximately one-third of 
and Tmax a half of that for S-ketoprofen after po and im administration. The inversion rate of R-
ketoprofen to S-ketoprofen is 70% in pigs (Neirinckx et al., 2011b), and pigs could be regarded as 
“extensive inverters”, as the inversion rate is above 50% (Aberg et al., 1995). The inversion process 
generally takes place in various organs (liver, intestine, kidney, and lung) and tissues (fatty and 
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muscle tissues), with the liver considered to be the most important organ (Cox et al., 1985; Mehvar 
and Jamali, 1988; Hall et al., 1992). Ketoprofen is metabolized in the liver and converted into a 
carbonyl-reduced derivative, 2-(phenyl 3-alphahydroxybenzoyl) propionic acid in swine (EMEA, 
1996). In rats, stereoselectivity has been reported for the biliary excretion process (Menzel et al., 
1993). The significance of stereoselectivity in reductive metabolism is difficult to assess, as 
inversion occurs in most species, and is rapid for ketoprofen (McEwen et al., 1998). 
Glucuronidation appears to be an important metabolic pathway for ketoprofen in pigs (EMEA, 
1996). Stereoselectivity of glucuronidation has been reported, but it is species and compound 
dependent (Caldwell et al., 1988). The possible stereoselectivity of ketoprofen glucuronidation in 
pigs has not been studied, but it could to some extent explain the more rapid elimination of R-
ketoprofen than S-ketoprofen. 
 
 
9.2 Ketoprofen plasma concentrations 
 
Ketoprofen concentrations persisted longer in plasma after oral administration of racemic 
ketoprofen than after intramuscular or intravenous administration at the same dose level. 
 
Fosse et al. (2011b) reported an IC50 for S-ketoprofen of 26.7 µg/mL and an IC50 for R-
ketoprofen of 1.6 µg/mL from mechanical nociceptive threshold testing in the kaolin-induced 
inflammation model in neonatal piglets. There have been no other reports on either the total or the 
enantiospecific therapeutic target concentration of ketoprofen in plasma for pigs. A total ketoprofen 
plasma concentration of 0.4–6 µg/mL has been recommended as a target therapeutic concentration 
in humans (McEvoy, 1991). A serum concentration of 0.2–0.4 µg/mL of S-ketoprofen is required 
for the maximum anti-inflammatory effect in adjuvant-induced arthritis in rats (Jamali and Brocks, 
1990), whereas at least 1 µg/mL of total ketoprofen is needed to alleviate pain in orthopaedic 
human patients (Kohler et al., 1985). In our study, the target therapeutic S-ketoprofen plasma 
concentration of 0.2–0.4 µg/mL was achieved for more than 12 hours after po administration of 
racemic ketoprofen at a dose of 4 mg/kg, and over 10 hours after im administration at a dose of 3 
mg/kg. The concentration of 1.6 µg/mL of R-ketoprofen was only achieved for two hours with these 
administration routes. Mean total ketoprofen plasma concentrations were at least 1 µg/mL for 10 
hours after po and im administration at a dose rate of 3 mg/kg, over 12 hours after po administration 
at a dose of 6 mg/kg and 8 hours after iv administration at a dose of 3 mg/kg. However, the possible 
stereoselectivity in plasma protein binding might affect the plasma-tissue ratio, and thus the 
effective plasma concentrations. Ketoprofen was present for longer in inflammatory exudates than 
in plasma (Landoni and Lees, 1995b; Landoni et al., 1995a; Landoni et al., 1995b; Landoni et al., 
1999; Arifah et al., 2001), and the clinical effect may therefore last longer than estimated from 
plasma concentrations. In contrast, plasma concentrations may not always correlate well with 
clinical signs, because the clinical effects are associated more with tissue concentrations. Fosse et 
al. (2011b) reported a biphasic analgesic effect in piglets; an initial comprehensive but short 
analgesia followed by a moderate but more sustained analgesia. The authors hypothesized that the 
short potent analgesia was due the action of R-ketoprofen, while S-ketoprofen was responsible for 
the longer-lasting moderate analgesia.  
 
 
 
 
 
44 
9.3 Efficacy in the treatment of endotoxemia  
 
Ketoprofen significantly reduced the rectal temperature at doses of 2 and 4 mg/kg, but not at the 
two lower doses (0.5 and 1 mg/kg). Ketoprofen treatment also significantly lowered the mean 
plasma TXB2 concentrations and total clinical scores compared to the control group. Our study 
indicates that oral administration of ketoprofen could be effective in the treatment of endotoxemia 
in pigs. Both 2 and 4 mg/kg were shown to be efficacious as a dose, with no significant difference 
between them. Thus, 2 mg/kg can be considered a sufficient oral dose of ketoprofen for treating 
endotoxemia in pigs, as increasing the dose above this did not further increase the effect. However, 
in an earlier study in piglets, ED50 was found to be 2.5 mg/kg im, suggesting that a higher dose 
might be beneficial in some cases (Fosse et al., 2011b). 
 
In our study, rectal temperatures and plasma TXB2 concentrations were elevated for up to 4 
hours after endotoxin (4 µg/kg) challenge in control pigs, thus confirming the proper functioning of 
the model (Schmidt and Banting, 2000; Banting et al., 2003). Although ketoprofen treatment was 
efficient compared to placebo, no significant differences could be detected between different dose 
rates with respect to the total clinical score and plasma TXB2 concentrations. In an earlier study, 
meloxicam treatment failed to detect significant differences compared to placebo in the total clinical 
response when pigs were endotoxin challenged at a dose of 4 µg/kg (Friton et al., 2006). At a higher 
dose of endotoxin (6 µg/kg), there was a greater clinical response in the placebo-treated pigs, and 
the total clinical score was significantly lower in the meloxicam-treated group compared to placebo 
treatment (Friton et al., 2006). We might also have detected more pronounced differences between 
the groups if we had used a higher endotoxin dose, but on the other hand this might have caused 
more undesirable side effects.  
 
A high TXB2 concentration before administration of ketoprofen, suggesting a potent acute 
response to endotoxin, was associated with more severe clinical signs, regardless of the ketoprofen 
dose. The TXB2 concentration has been reported to markedly increase, followed by a rapid decline, 
with the peak occurring within 20 min of endotoxin administration in pigs (Webb et al., 1981; Ball 
et al., 1986). In our study, the peak occurred within 30 min and there was an obvious decline by 60 
min after endotoxin exposure, although the mean concentrations of all the groups were still higher 
than the baseline, and remained high in the control group up to 4 hours post-challenge. 
 
In our study, the mean plasma TXB2 concentrations were reduced even at the low ketoprofen 
plasma concentrations determined in the low dose groups, hence confirming previous findings of 
effective inhibition of TXB2 production (Landoni and Lees, 1995a; Landoni et al., 1999; Arifah et 
al., 2001). Rectal temperatures were also reduced, although the measured ketoprofen plasma 
concentrations were low. This supports previous findings of a good antipyretic efficacy of 
ketoprofen in pigs (Arnaud and Consalvi, 1994; Swinkels et al., 1994; Salichs et al., 2012).  
  
The sampling point chosen for determination of the ketoprofen plasma concentration of 
endotoxin challenged pigs was based on study I, in which the maximum plasma concentration was 
detected approximately 1 hour after oral administration of ketoprofen in healthy pigs. In the 
endotoxin challenge study, plasma concentrations in most pigs at this sampling point were much 
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lower than in our previous study in healthy pigs administered similar doses, and the individual 
variation was considerable. As we did not investigate the pharmacokinetics of ketoprofen in these 
endotoxin-challenged pigs, the precise reason for this variability remains unknown. However, the 
absorption, distribution, metabolism and excretion of drugs may be altered by endotoxin exposure 
(Yang and Lee, 2008). The maximum plasma concentration had possibly not been reached at the 
time of sampling. Gastric emptying and gastrointestinal absorption may be delayed in endotoxemia 
(Hurwitz et al., 1975; Haque et al., 1997). On the other hand, the absorption of drugs could be 
reduced due to the development of diarrhoea (Yang and Lee, 2008). In dairy cows, the response to 
oral ketoprofen treatment in endotoxic mastitis was as rapid and effective as that to intramuscular 
treatment, despite decreased rumen motility after challenge and before treatment (Banting et al., 
2008). In our study, the dose was administered by syringe into the mouth, not with a tube into the 
stomach, to reflect clinical practice. Therefore, some spillage could have occurred, although no 
notable spilling was observed. As absorption may be reduced and delayed in endotoxemic animals, 
and variation in ketoprofen plasma concentrations between individual animals could be 
considerable, it might be advisable to use the parenteral administration route at least in animals with 
severe endotoxemia (Hurwitz et al., 1975; Choi et al., 2007).  
 
 
9.4 Efficacy in the treatment of lameness 
 
Our study demonstrated that oral ketoprofen was efficient in alleviating the signs of non-
infectious lameness in sows and gilts. The treatment success rates agreed with previous results 
using meloxicam in lame pigs (Friton et al., 2003). In our study, there was no difference in efficacy 
between 2 mg/kg and 4 mg/kg doses. The smaller dose was cheaper, easier to administer and may 
have caused a smaller risk of adverse effects. The findings support the use of oral ketoprofen at 2 
mg/kg for up to 5 consecutive days in treating locomotor disorders in pigs.  
   
Diagnosing non-infectious lameness in sows by clinical examination is difficult. In most cases, 
post-mortem examinations are needed to correctly diagnose the cause of lameness (Dewey et al., 
1993; Engblom et al., 2008). In our study, the cause of non-infectious lameness was not determined 
and diagnosis was based on a thorough clinical examination and analysis of blood samples. Any 
indication for antibiotics prior to, during or after the treatment was an exclusion criterion. The 
leukocyte count, haemoglobin and haptoglobin concentrations and PCV values were lower in 
healthy pigs than in those with an inflammatory process (Odink et al., 1990). In the present study, 
blood values were within the reference ranges previously reported for healthy pigs (Friendship et 
al., 1984; Heinonen et al., 2006), confirming the non-infectious nature of the lameness. 
 
Ketoprofen treatment proved to be more efficient on farms with solid concrete or partly slatted 
floors than on farms with fully slatted floors. The prevalence of lameness was greater among pigs 
housed on fully slatted floors than on solid floors (Jorgensen, 2003), but no previous studies have 
been conducted on the effect of floor type on treatment efficacy. Deep bedding reduced the risk of 
abnormal gait (Kilbride et al., 2009). Due to the limited number of animals in this study, no 
statistical analysis was performed to evaluate the influence of deep litter bedding on treatment 
success. However, providing a lame animal with a sufficient amount of bedding should improve the 
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tolerance of pain and was therefore considered helpful as an adjunct to the use of analgesics in pain 
management (Short, 1998). 
 
 
9.4 Tolerance 
 
Undesirable side effects of ketoprofen are typical for non-selective NSAIDs, with 
gastrointestinal irritation being the most frequently found adverse effect (Wallace 1997). The risk 
increases as the plasma concentration of the active ingredient increases. Although the medication 
period was longer (in study IV) and dose rates higher (in all studies) than the approved duration and 
dose rate, no adverse events caused by use of ketoprofen were clinically observed. However, non-
clinical adverse effects were detected in necropsy. Six pigs had ulcers in the mucosa in the 
glandular part, which indicated gastrointestinal irritation due to ketoprofen. In humans, ulcers in the 
stomach or small intestine occur in up to 40% of patients taking NSAIDs, although most of these 
ulcers can only be found by endoscopy because they do not cause symptoms (Hawkey et al., 2000; 
Laine et al., 2004). Gastric ulceration is also a frequent problem in horses, in which the clinical 
signs are variable and non-specific. Alternatively, horses may be asymptomatic (Bell et al., 2012). 
Horses with pre-existing glandular lesions were affected by ketoprofen treatment, and an increase in 
the number and severity of lesions was observed after ketoprofen administration (MacAllister et al., 
1993). Dogs tend to have gastrointestinal irritation after ketoprofen medication, although the lesions 
were reported to heal after administration was discontinued and were not therefore considered 
clinically relevant in healthy dogs (Narita et al., 2005). Tolerance studies are usually performed in 
healthy animals. As anorexia and dehydration are possible risk factors for adverse events of 
NSAIDs, supportive care should be taken into consideration when medicating diseased animals. 
 
Although the endotoxin dose used in study III was moderate, two pigs spontaneously died, 
despite treatment with a low dose (1 mg/kg) of ketoprofen. Higher endotoxin doses of 10–20 µg/kg 
have been used in pigs with no reports of mortality (De Saedeleer et al., 1992; Myers et al., 2010). 
The cause of the deaths remained uncertain. Fatty degeneration of the liver of one of the dead pigs 
might have been, at least to some extent, the underlying cause. The post-mortem examination 
revealed no findings that would have seem to be caused by the use of ketoprofen itself.  
 
Lame animals often require NSAID medication for several days. In our study, the efficacy of 
oral ketoprofen was comparable with that of injectable meloxicam in a previous study (Friton et al., 
2003). Although injectable ketoprofen and meloxicam are not as irritating to the tissues as some 
other NSAIDs, they do cause local tissue damage after im injection (Pyorala et al., 1999; Magyan 
and Glávits, 2007). Oral administration is therefore less painful and animal friendly for longer-term 
medication. However, the long-term side effects of the treatment need to be elucidated. Lameness is 
also a common problem in piglets, and it indicates pain and might reduce growth rates (Zoric et al., 
2003). However, further pharmacological studies are required before recommendations for the use 
of oral ketoprofen in piglets can be made, since there may be differences in pharmacokinetics in 
neonatal pigs compared to older ones. Fosse et al. (2011a) reported a higher clearance rate and 
larger volume of distribution in 6-day-old than 21-day-old pigs. 
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10. CONCLUSIONS 
1. S-ketoprofen is the predominant enantiomer in pig plasma after the administration of 
racemic ketoprofen via oral and intramuscular routes. The relative bioavailability of S-ketoprofen 
was higher than for R-ketoprofen after oral administration. 
 
2. After administration of racemic ketoprofen at dose rates of 3 mg/kg or 6 mg/kg po, 
and 3 mg/kg im, bioequivalence could not be detected.  
 
3. An oral dose of 2 mg/kg racemic ketoprofen could be considered as appropriate for 
treating induced endotoxemia in pigs. 
 
4. Spontaneous non-infectious lameness of sows and gilts could be efficiently treated 
with racemic oral ketoprofen at a dose rate of 2 mg/kg for five consecutive days. 
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